Treatment of cancer

MD Anderson Finds Energy Emitted from Sean Harribance Affects Cancer Cells

Retrieved on: 
Tuesday, February 9, 2021

For the past 10 years, the University of Texas MD Anderson Cancer Center has been conducting research with Sean Harribance.

Key Points: 
  • For the past 10 years, the University of Texas MD Anderson Cancer Center has been conducting research with Sean Harribance.
  • Their most recent research also found that exposure to Mr. Harribance reduced cancer stem cells, cells that even conventional treatments cannot destroy.
  • "Our research has shown that Sean Harribance also has the ability to change cancer cell function in other cell lines such as breast cancer.
  • We believe the effects Sean Harribance has had with lung cancer can be applied to many other cancers," commented Dr. Cohen.

Fibralign Announces Start of European Lymphedema Prevention Clinical Study

Retrieved on: 
Tuesday, February 9, 2021

Peer reviewed publications have estimated that 15-25% of patients who undergo ALND develop breast cancer-related lymphedema (BCRL) due to the surgery.

Key Points: 
  • Peer reviewed publications have estimated that 15-25% of patients who undergo ALND develop breast cancer-related lymphedema (BCRL) due to the surgery.
  • Lymphedema is a serious, global, progressive disease that can develop as a result of cancer treatments.
  • The certification mark confirms that BioBridge meets the requirements of the European Medical Devices Directive, which now allows Fibralign to market the product across the European Union and other CE mark countries.
  • Published preclinical studies and early clinical usage have shown that BioBridge supports the repair of damaged lymphatic vessels that causes lymphedema.

United States Lung Cancer Market 2021: Pipeline Products, Market Analysis, Epidemiology, Key Products Marketed, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 9, 2021

This latest research report provides comprehensive insights into Lung Cancer pipeline products, Lung Cancer epidemiology, Lung Cancer market valuations and forecast, Lung Cancer drug sales and a competitive landscape in the US.

Key Points: 
  • This latest research report provides comprehensive insights into Lung Cancer pipeline products, Lung Cancer epidemiology, Lung Cancer market valuations and forecast, Lung Cancer drug sales and a competitive landscape in the US.
  • The research is classified into seven sections - Lung Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Lung Cancer drugs: Identify key products marketed and prescribed for Lung Cancer in the US, including trade name, molecule name, and company
    Lung Cancer market valuations: Find out the market size for Lung Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Lung Cancer drugs market share: Find out the market shares for key Lung Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Lung Cancer products

Worldwide Cancer Biological Toxins Drug Industry to 2026 - Featuring Angimmune, Astrazeneca and Sanofi Among Others

Retrieved on: 
Friday, February 5, 2021

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:
    Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
    Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
    Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
    Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)
    While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable.
  • Immune Checkpoint Inhibitor Therapy
    4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
    4.2.1 Cancer Biological Toxin Therapy Market Vs.
  • Radiation Therapy for Cancer Treatment
    4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer

Retrieved on: 
Thursday, February 4, 2021

"Women who are being or who have previously been treated for hormone-sensitive cancers should not use hormonal birth control because it may stimulate the growth of tumor cells," said Gury Doshi, M.D., Texas Oncology.

Key Points: 
  • "Women who are being or who have previously been treated for hormone-sensitive cancers should not use hormonal birth control because it may stimulate the growth of tumor cells," said Gury Doshi, M.D., Texas Oncology.
  • "As a survivor of Stage III breast-cancer, this collaboration with NCODA is extremely important to me and to the entire Evofem team," said Saundra Pelletier, CEO of Evofem Biosciences.
  • "I understand firsthand the extraordinary suffering - physical, mental, psychological and sexual - that women face during and after cancer treatment.
  • Phexxi is a registered trademark of Evofem Biosciences, Inc.
    Phexxi is an on-demand method of birth control used to prevent pregnancy.

Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.

Retrieved on: 
Tuesday, February 2, 2021

Under the agreement, which supersedes the previous collaboration agreement between the companies announced in October 2020, Oncocyte will acquire the intellectual property (IP) and technology for Chronixs TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronixs organ transplant technology.

Key Points: 
  • Under the agreement, which supersedes the previous collaboration agreement between the companies announced in October 2020, Oncocyte will acquire the intellectual property (IP) and technology for Chronixs TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronixs organ transplant technology.
  • The initial focus will be on clinical studies in lung cancer and other solid tumor types treated by immunotherapy.
  • Chronix Biomedical, Inc. is aprivately held, U.S.-based molecular diagnostics company developing blood tests for use in cancer treatment and organ transplantation.
  • Chronix Biomedical has operations in theU.S.&Germany, and the commercial launch of their products began in the EU in 2018.

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

Retrieved on: 
Tuesday, January 19, 2021

(NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center.

Key Points: 
  • (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center.
  • The trial will assess the combination of Lixtes first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).
  • John S. Kovach, M.D., Lixte founder and chief executive officer, said Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the US.
  • We look forward to working with Lixte on this important trial that we hope will make more therapeutic options available for patients with small cell lung cancer.

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients

Retrieved on: 
Monday, January 18, 2021

Propanc Biopharma, Inc. (OTC: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers.

Key Points: 
  • Propanc Biopharma, Inc. (OTC: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers.
  • The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), multi-trial center studies for each target indication.
  • The expressions of interest were confirmed after evaluation of Propancs scientific literature supporting the use of proenzymes in pancreatic and ovarian cancers.
  • Propanc Biopharma, Inc. (the Company) is developing a novel cell differentiation therapy using pancreatic proenzymes that target and eradicate cancer stem cells to prevent recurrence and metastasis of solid tumors in patients suffering from pancreatic, ovarian and colorectal cancers.

Mount Sinai Researcher Receives NCI Grant to Study New Strategies to Prevent Cancer Metastasis

Retrieved on: 
Monday, January 11, 2021

This delay in growth is mediated by a process called tumor dormancy, in which tumor cells cease dividing but can be reactivated under the right environmental conditions.

Key Points: 
  • This delay in growth is mediated by a process called tumor dormancy, in which tumor cells cease dividing but can be reactivated under the right environmental conditions.
  • These cells are less vulnerable to the immune system and cancer treatments, including chemo and radiation.
  • The study will use high-resolution imaging tools combined with dormancy models to study tumor cell-ECM interactions during dormancy.
  • For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers

Retrieved on: 
Monday, January 11, 2021

Propanc Biopharma, Inc. (OTC: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting solid tumors such as pancreatic, ovarian and colorectal cancers.

Key Points: 
  • Propanc Biopharma, Inc. (OTC: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting solid tumors such as pancreatic, ovarian and colorectal cancers.
  • At Propanc, we share a vision to develop and commercialize a novel approach using pancreatic proenzymes for the long-term treatment and prevention of metastatic cancer from solid tumors.
  • Eighty percent of cancers are from solid tumors and metastasis is the main cause of patient death, therefore the potential of cell differentiation therapy using pancreatic proenzymes is significant.
  • Propanc Biopharma, Inc. (the Company) is developing a novel cell differentiation therapy using pancreatic proenzymes that target and eradicate cancer stem cells to prevent recurrence and metastasis of solid tumors in patients suffering from pancreatic, ovarian and colorectal cancers.